th In Biophy iophytis is to to Presen Present at t at the the - - PDF document

Pr Press ss Releas lease

Biophy iophytis is to to Presen Present at t at the the 15 15th

th In

Interna ernati tional

• nal Con

Congress of gress of the the Euro European Ger pean Geriatric M iatric Medicine S edicine Socie

• ciety

ty in in Kr Krakow, akow, Poland Poland

Paris Paris (Franc rance), Ca Camb mbridge ridge (Mas Massach chus usett tts, Unit nited Sta tates), September 26, 2019, 8:00 AM CEST - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of drug candidates for the treatment of age-related diseases, announces that Waly Dioh, VP Clinical Development, will make a presentation titled, “Evaluation of Safety and Efficacy of BIO101, a Mas Receptor Activating Drug for Sarcopenia: A Double-blind, Placebo Controlled, Randomized Clinical Trial” at the 15th International Congress of the European Geriatric Medicine (EuGMS). The Congress is taking place between 25th and 27th September 2019 in Krakow, Poland. Biophytis’ clinical development plan for Sarconeos (BIO101) for the treatment of sarcopenia comprises:

• SARA-PK, a Phase 1 clinical trial that showed safety and tolerability in older healthy volunteers. The

trial completed in 2017.

• SARA-OBS, an observational trial that was completed in Q2 2019 with the last patient out, and
• SARA-INT, an ongoing international Phase 2b trial with a 6-month follow-up period that is currently

recruiting patients in the US and Europe. The primary endpoint of the study is the 400-meter walking test gait speed. In his presentation Mr. Dioh will:

• Outline the SARA-OBS study, which was designed to characterize, pre-recruit and confirm the optimal

patient population for the SARA-INT trial, and

• Provide data on the preliminary baseline characteristics and changes from baseline of the first set of

SARA-OBS patients. In addition, insights on the SARA-INT recruitment strategies, including inclusion criteria, as well as the baseline characteristics of the first patients, will be discussed. The presentation will be made today at 2:30 PM CEST. **** Ab About

• ut Sarcon

rconeos ( (BIO1 O101) Biophytis’s lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule for the treatment

• f neuromuscular diseases. Sarconeos (BIO101) is a plant-derived pharmaceutical-grade purification of 20-
• hydroxyecdysone. Pre-clinical studies have shown that (Sarconeos) BIO101 stimulates biological resilience

through activation of the MAS receptor, which suggests preservation of muscle strength, function and mobility in various muscular wasting conditions. Biophytis is currently testing Sarconeos (BIO101) in a global, randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial (SARA-INT) on patients with sarcopenia, a disease of ageing characterized by a loss of muscle mass, strength and function in elderly people leading to mobility disabilities, an increased risk of adverse health events and potential death.

Pr Press ss Releas lease

Ab About

• ut Bi

Biop

• phy

hyti tis Biophytis is a clinical-stage biotechnology company focused on developing therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, with a primary focus on neuromuscular diseases. Biophytis’ lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule, which is currently in a Phase 2b clinical trial for sarcopenia (SARA-INT) in the US and Europe. Sarconeos (BIO101) is also being developed for the treatment of Duchenne muscular dystrophy (DMD). Biophytis expects Sarconeos (BIO101) to be ready to enter the clinic for DMD in 2020. Biophytis is headquartered in Paris, France, and has offices in Cambridge, Massachusetts. The Company’s

• rdinary shares are listed on Euronext Growth Paris (Ticker: ALBPS - ISIN: FR0012816825). For more

information please visit www.biophytis.com. Discla Disclaime mer This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Euronext Growth of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf- france.org) or on Biophytis’ website (www.biophytis.com). This press release and the information contained herein do not constitute an offer to sell or a solicitation of an

• ffer to buy or subscribe to securities of Biophytis in any country. Existing and prospective investors are

cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, Biophytis undertakes no obligation to update

• r revise the information contained in this press release. This press release has been prepared in both French

and English. In the event of any differences between the two texts, the French language version shall prevail. Bi Bioph

• phyti

tis Investor tor Re Relati tions

• ns Conta

Contact ct Daniel Schneiderman, CFO dan.schneiderman@biophytis.com Tel: +1 (857) 220-9720 U.S. Media dia Conta Contact ct LifeSci Public Relations Cherilyn Cecchini, M.D. ccecchini@lifescipublicrelations.com Tel: +1 (646) 876-5196 Eur Europ

• pe Medi

Media Conta Contact ct Citigate Dewe Rogerson Quentin Dussart / Sylvie Berrebi / Nathaniel Dahan / David Dible biophytis@citigatedewerogerson.com

Pr Press ss Releas lease

Tel: +33 (0)1 55 30 70 91 / +44 (0)20 76389571 Source : Biophytis